RT Journal Article
SR Electronic
T1 Survival outcomes are associated with genomic instability in luminal breast cancers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.25.20027920
DO 10.1101/2020.02.25.20027920
A1 Lydia King
A1 Andrew Flaus
A1 Aaron Golden
YR 2020
UL http://medrxiv.org/content/early/2020/02/26/2020.02.25.20027920.abstract
AB Breast cancer is the leading cause of cancer related death among women. Breast cancers are generally diagnosed and treated based on clinical and histopathological features, along with subtype classification determined by the Prosigna Breast Cancer Prognostic Gene Signature Assay (also known as PAM50). Currently the copy number alteration (CNA) landscape of the tumour is not considered. We set out to examine the role of genomic instability (GI) in breast cancer survival since CNAs reflect GI and correlate with survival in other cancers. We focussed on the 70% of breast cancers classified as luminal and carried out a comprehensive survival and association analysis using Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) data to determine whether CNA burden quartiles derived from absolute CNA counts are associated with survival. Luminal A and B patients were stratified by PAM50 subtype and tumour grade and then tested for association with CNA burden using multiple statistical tests. Analysis revealed that patients diagnosed with luminal A grade 3 breast cancer have a CNA landscape associated with disease specific survival, suggesting that these patients could be classified as at-risk. Furthermore, luminal A grade 3 cases largely occupy a region of stratification based on gene expression at the boundary where luminal A and luminal B cases overlap. We conclude that GI reflected by absolute CNA score is a statistically robust prognostic factor for survival in luminal A grade 3 breast cancer. Therefore, luminal A grade 3 breast cancer patients in CNA burden quartiles 3 or 4 may benefit from more aggressive therapy. This demonstrates how individual genomic landscapes can facilitate personalisation of therapeutic interventions to optimise survival outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis publication has emanated from research conducted with the financial support of Science Foundation Ireland under Grant number [18/CRT/6214]Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll processed data products from the METABRIC consortium used in this work are freely available courtesy of the cBioportal for Cancer Genomics webportal. https://www.cbioportal.org/study/summary?id=brca_metabric